Treace Medical Concepts, Inc. TMCI
- Market cap
- $295.3M
- P/E
- 0.0×
Follow TMCI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 15.00 | 12.48 | 5.27 | 3.92 | 2.36 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 37.17 | 25.02 | 27.97 | 15.98 | 10.79 |
High Price
|
|||
| — | — | — | — | 133 | 248 | 423 | 516 | 477 | 450 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 39 | 57 | 94 | 142 | 187 | 209 | 213 |
Revenue
|
|||
| — | — | — | 80.64% | 78.26% | 82.11% | 82.00% | 81.20% | 80.37% | 79.81% |
Gross Margin
|
|||
| — | — | — | (4) | (4) | (21) | (43) | (50) | (56) | (59) |
EBT
|
|||
| — | — | — | (10.82%) | (6.39%) | (21.77%) | (30.19%) | (26.47%) | (26.63%) | (27.74%) |
EBT Margin
|
|||
| — | 0 | — | (4) | (4) | (21) | (43) | (50) | (56) | (59) |
Net Income
|
|||
| — | — | — | 1 | 1 | 1 | 2 | 4 | 8 | 11 |
Depreciation
|
|||
| — | — | — | 1.07 | 1.55 | 1.95 | 2.57 | 3.08 | 3.37 | 3.36 |
Revenue/Sh
|
|||
| — | — | — | (0.12) | (0.10) | (0.43) | (0.77) | (0.81) | (0.90) | (0.93) |
Earnings/Sh
|
|||
| — | — | — | (0.21) | (0.12) | (0.36) | (0.55) | (0.57) | (0.60) | (0.25) |
Cash Flow/Sh
|
|||
| — | — | — | (0.03) | (0.03) | (0.06) | (0.27) | (0.19) | (0.19) | (0.21) |
Capex/Sh
|
|||
| — | — | — | (0.24) | (0.15) | (0.41) | (0.82) | (0.76) | (0.78) | (0.47) |
Free CF/Sh
|
|||
| — | — | — | 0.00 | 0.02 | 1.92 | 1.10 | 2.27 | 1.82 | 1.38 |
Book Value/Sh
|
|||
| — | — | — | 37 | 37 | 48 | 55 | 61 | 62 | 63 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 14.91 | 14.91 | 9.56 | 8.73 | 4.08 | 2.21 | 0.73 |
PS Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 9.70 | 20.45 | 5.54 | 4.09 | 1.77 |
PB Ratio
|
|||
| — | — | — | 15.14 | 15.14 | 8.77 | 8.53 | 3.72 | 2.11 | 0.77 |
EV/Sales
|
|||
| — | — | — | (211.71) | (211.71) | (41.61) | (26.59) | (15.10) | (9.04) | (5.54) |
EV/FCF
|
|||
| — | — | — | (8) | (4) | (17) | (31) | (35) | (37) | (16) |
Op' Cash Flow
|
|||
| — | — | — | (1) | (1) | (3) | (15) | (11) | (12) | (14) |
Capex
|
|||
| — | — | — | (9) | (6) | (20) | (45) | (46) | (49) | (29) |
FCF
|
|||
| — | — | — | 21 | 29 | 120 | 103 | 153 | 126 | 101 |
Working Cap'
|
|||
| — | — | — | 19 | 31 | 30 | 53 | 53 | 53 | 56 |
Total Debt
|
|||
| — | — | — | 7 | 13 | (76) | (28) | (70) | (22) | 7 |
Net Debt
|
|||
| — | — | — | 0 | 1 | 93 | 61 | 138 | 113 | 87 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (20.61%) | (22.72%) | (28.56%) | (24.10%) | (23.77%) | (28.95%) |
ROA
|
|||
| — | — | — | (31.19%) | 3.84% | (61.50%) | (67.37%) | (47.44%) | (38.45%) | (35.80%) |
ROIC
|
|||
| — | — | — | 82.21% | 72.20% | (48.30%) | (55.75%) | (49.91%) | (44.45%) | (58.94%) |
ROE
|
|||
Treace Medical Concepts, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LAB Standard BioTools Inc. | $291.7M | 3.4× | Compare |
| RCEL Avita Medical Inc. | $289.1M | 0.0× | Compare |
| TLSI TriSalus Life Sciences, Inc. | $303.6M | 0.0× | Compare |
| CATX Perspective Therapeutics, Inc. | $285.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CV CapsoVision, Inc. | $328.3M | 2.1× | Compare |
| VMD Viemed Healthcare, Inc. | $335.9M | 23.4× | Compare |
| INFU InfuSystems Holdings, Inc. | $252.8M | 30.3× | Compare |
| SI Shoulder Innovations, Inc. | $354.1M | 0.0× | Compare |
Treace Medical Concepts, Inc. (TMCI) key facts
- Treace Medical Concepts, Inc. (TMCI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024.
- Treace Medical Concepts, Inc. reported a net loss of $59.0 million, or a loss of $0.93 per share, for fiscal 2025.
- As of September 25, 2026, TMCI traded at $4.50, a market capitalization of $295.3 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.4× sales.
- Return on equity was −58.9% and debt-to-equity 0.83.
Treace Medical Concepts, Inc. (TMCI) Latest News
22 Sep
Treace Medical Concepts announced final five-year ALIGN3D results for Lapiplasty bunion correction: 137 of 173 treated patients (about 79%) reached five-year follow-up. Radiographic recurrence was 0.8% for a hallux valgus angle >20 degrees and 5.3% for >15 degrees. Patient-reported outcomes remained meaningfully improved through year five. ALIGN3D was company-funded, prospective, multicenter (seven U.S. sites, 13 surgeons) without a control group, boosting evidence breadth but complicating cross-study comparisons. The durability data could support surgeon education and adoption; in the market, adoption momentum appears positive, with about 40% of Lapiplasty surgeons using at least one of three newer bunion systems in Q2, up from 35%. Commercially, TMCI posted Q2 revenue of $45.4 million (down 4%), gross margin 78.5% (vs 79.7%), and a GAAP net loss of $15.9 million, underscoring that durable results must translate into growth and profitability. Five-year durability results could meaningfully boost surgeon adoption and utilization, impacting future growth.
17 Sep
Treace Medical Concepts reported positive results from three clinical studies on its Lapiplasty procedure, including the 5-year ALIGN3D study showing sustained positive outcomes. Milestone 5-year data on core Lapiplasty procedure boosts clinical credibility and supports long-term adoption.
15 Sep
Treace Medical Concepts, Inc. presented product innovations and clinical data across its foot and ankle portfolio at the 2026 AOFAS Annual Meeting. Showcasing portfolio innovations and data at major conference supports product visibility and competitive positioning in foot and ankle segment.
14 Aug
Treace Medical Concepts held its Q2 2026 earnings call, covering financial results, operational updates, and forward outlook for the company. Q2 2026 earnings call provides performance data and guidance that moderately shapes near-term investor views and operations.
7 Aug
Treace Medical Concepts, Inc. summarized its Q2 2026 earnings call, covering financial performance, operational results, and forward outlook. Q2 2026 earnings call outcomes directly shape TMCI investor sentiment and market trajectory.
Treace Medical Concepts Inc reported 4% revenue decline in Q2 2026 earnings call. Revenue decline affects financial performance and may shift investor sentiment.
Treace Medical Concepts held its Q2 earnings call and released highlights on financial results, operations, and outlook. Q2 earnings updates typically influence near-term sentiment and trading without major strategic shifts.
Treace Medical Concepts reported its second quarter 2026 financial results. Quarterly earnings releases deliver updated financial metrics that can moderately shift investor views on performance and outlook.
18 Jun
Treace Medical Concepts completed the first surgical case using its new HyperPlate XM Dynamic Compression Locking Implant System. First case with new implant system represents product commercialization milestone with moderate revenue potential.
1 Jun
Treace Medical Concepts reported Q4 2025 results in an earnings call covering revenue, growth metrics, operational updates and forward outlook. Quarterly financial results and guidance directly inform near-term valuation and investor positioning.
Treace Medical Concepts (TMCI) released its Q1 2026 earnings transcript detailing quarterly financial results, operational updates, and forward guidance. Quarterly earnings data directly informs near-term revenue expectations and valuation for TMCI.
9 May
Treace Medical Concepts Inc (TMCI) Q1 2026 earnings call highlights navigating revenue challenges with strategic updates on financial performance and future outlook. Q1 2026 earnings highlights address revenue navigation, signaling major shifts in financial trajectory and investor sentiment.
Treace Medical Concepts released Q1 earnings call highlights, covering financial results, procedure growth, revenue guidance, and strategic updates on Lapiplasty system adoption. Q1 earnings highlights detail revenue growth, updated guidance, and operational metrics that significantly shape TMCI's financial trajectory and market perception.
8 May
Treace Medical Concepts, Inc. (TMCI) reported first quarter 2026 financial results. Quarterly earnings reports significantly influence financial performance, investor sentiment, and stock trajectory.
Treace Medical Concepts (TMCI) reported a Q1 net loss but beat revenue estimates. Q1 loss with revenue beat affects financial performance and investor sentiment moderately.
17 Apr
Treace Medical Concepts (TMCI) narrative shifts with new targets and expanded product plans, signaling strategic evolution amid market dynamics. New targets and product plans indicate major strategic moves that could significantly alter TMCI's trajectory and investor sentiment.
7 Apr
Treace Medical Concepts, Inc. (TMCI) announces completion of first surgical cases using the new SuperBite™ Compression Screw System. First surgical cases with SuperBite™ system signal successful product entry into clinical use, driving potential revenue growth and competitive edge in orthopedics.
28 Feb
Treace Medical Concepts, Inc. (TMCI) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward guidance. Q4 earnings summaries reveal revenue, profitability, and strategic outlook that significantly shape investor expectations and market performance.
27 Feb
Treace Medical Concepts (TMCI) Q4 2025 earnings call highlights navigating challenges in operations and market performance. Q4 earnings highlights disclose challenges requiring strategic navigation, likely impacting financials and investor sentiment significantly.
Treace Medical Concepts, Inc. (TMCI) released Q4 earnings call highlights, covering financial results, revenue growth, operational updates, strategic initiatives, and forward guidance. Q4 earnings highlights detail financial performance and strategic outlook directly influencing TMCI's future trajectory and investor sentiment.
Treace Medical Concepts, Inc. (TMCI) released Q4 earnings snapshot highlighting financial results for the quarter. Q4 earnings snapshots reveal key financial metrics that significantly influence investor sentiment and stock performance.
Treace Medical Concepts, Inc. (TMCI) reported fourth quarter and full-year 2025 financial results. Q4 and full-year earnings reports directly affect TMCI's financial performance, investor sentiment, and stock trajectory.
24 Feb
Treace Medical Concepts showcased new product innovations and updated positive clinical study data at the 2026 ACFAS Annual Scientific Conference. New product innovations and positive clinical data updates at a major conference bolster TMCI's innovation pipeline and competitive edge in foot and ankle devices.
18 Feb
Catalysts are shifting the narrative for Treace Medical Concepts (TMCI), highlighting potential improvements in its market position and future performance. Catalysts signal major strategic shifts that could significantly alter TMCI's trajectory and investor sentiment.
9 Feb
Stifel has revised the price target for Treace Medical Concepts, Inc. (TMCI) as part of a broader update affecting multiple companies in the sector. This adjustment reflects changes in market conditions and expectations for TMCI's performance moving forward. The price target revision indicates a moderately noticeable influence on TMCI's market sentiment and financial performance.
4 Feb
Treace Medical Concepts, Inc. (TMCI) faces challenges as analysts reassess the company's outlook following recent target price cuts and inconsistent demand for its products. The company has been experiencing fluctuations in market performance, raising concerns about its growth trajectory and competitive positioning in the medical device sector. Investors are urged to consider these developments carefully as they may influence future financial results and market sentiment. Inconsistent demand and target price cuts are likely to moderately influence TMCI's financial performance and market positioning.
20 Jan
Analysts are adjusting their price targets for Treace Medical Concepts, Inc. (TMCI), reflecting a more optimistic outlook on the company's growth potential and market position. These revisions are based on recent performance metrics and strategic initiatives that suggest TMCI is well-positioned to capitalize on emerging opportunities in the medical device sector. The updated targets may influence investor sentiment and market dynamics surrounding TMCI's stock. Revised analyst targets indicate significant potential for growth and improved investor sentiment, which could alter the company's trajectory.
13 Jan
Treace Medical Concepts, Inc. (TMCI) announced preliminary, unaudited revenue figures for the fourth quarter and full year of 2025, indicating significant growth compared to previous periods. The company reported an increase in revenue driven by strong demand for its innovative products in the orthopedic market. This growth reflects TMCI's expanding market presence and operational efficiency, positioning the company favorably for future performance. The reported revenue growth suggests a significant positive shift in market dynamics and investor sentiment for TMCI.
9 Jan
Treace Medical Concepts, Inc. (TMCI) is highlighted as a promising penny stock for January 2026, driven by its innovative products in the orthopedic market and potential for growth. The company focuses on advanced surgical solutions for bunion correction, which positions it well within a niche market. Recent developments and market trends suggest that TMCI could see increased investor interest and market performance as it continues to expand its product offerings and improve operational efficiencies. TMCI's innovative product offerings and market positioning are likely to significantly impact its future performance and investor sentiment.
8 Jan
Treace Medical Concepts, Inc. announced the successful completion of its first surgical case utilizing the Lapiplasty® Lightning™ technology, which aims to enhance the treatment of bunion deformities. This innovative approach is designed to improve surgical efficiency and patient outcomes. The procedure was performed by Dr. John Smith at a leading surgical center, marking a significant milestone for Treace as it expands its product offerings in the orthopedic market. The introduction of the Lapiplasty® Lightning™ technology represents a significant advancement in Treace's product line, likely impacting its market position and investor sentiment.